Katherine K. Matthay, MD

Professor, Department of Pediatrics, and Division Chief, Pediatric Hematology/Oncology, UCSF; Leader, Pediatric Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center
Mildred V. Strouss Endowed Chair in Translational Research in Pediatric Oncology, UCSF

Phone: (415) 476-3831 (appts)
Box 0106, UCSF
San Francisco, CA 94143-0106

View on UCSF Profiles

Additional Websites

• Physician Referral Directory

Education

Bryn Mawr College, Bryn Mawr, PA, B.A., 1969, Chemistry
University of Pennsylvania, Philadelphia, PA, M.D., 1973, Medicine
University of Colorado, Denver, CO, Resident, 1976, Pediatrics
University of California, San Francisco, CA, Fellow, 1979, Pediatric Hematology/Oncology

Professional Experience

• 1980-87
  Assistant Professor in Residence, Pediatrics, Univ. of Calif., San Francisco
• 1987-93
  Associate Professor in Residence, Pediatrics, Univ. of Calif., San Francisco
• 1991-2001
  Chair, Neuroblastoma Strategy Group, Children's Cancer Group
• 1992-present
  Chief, Pediatric Clinical Oncology, Univ. of California, San Francisco
• 1993-present
  Professor, Pediatrics, Univ. of California, San Francisco
• 2000-2001; 2009-10
  Visiting Professor, Institut Curie, Paris
• 2003-2006
  Fellowship Director, Pediatric Hematology/Oncology, Univ. of California, San Francisco
• 2003-present
  Division Chief, Pediatric Hematology/Oncology, Univ. of California, San Francisco
• 2005-present
  Leader, Pediatric Malignancies Program in the HDF Comprehensive Cancer Center

Honors & Awards

• 1992
  American Cancer Society Scholar Award
• 2000-01
  Bourse Henri de Rothschild for Neuroblastoma Research Award
• 2006
  Mildred V. Strouss Endowed Chair in Translational Research
• 2006-12
  SIOP North American continental President
• 2007
  Hadassah Doctor of Distinction Award

Selected Publications

1. Mueller S, Bhargava S, Molinaro AM, Yang X, Kolkowitz I, Olow A, Wehmeijer N, Orbach S, Chen J, Matthay KK, Haas-Kogan DA. Poly (ADP-Ribose) Polymerase Inhibitor MK-4827 together with Radiation as a Novel Therapy for Metastatic Neuroblastoma. Anticancer Res. 2013 Mar; 33(3):755-62.
   View on PubMed
2. Dubois SG, Matthay KK. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013 Mar; 57(1):53-65.
   View on PubMed
3. Depasse J, Caniza MA, Quessar A, Khattab M, Hessissen L, Ribeiro R, Cherkaoui S, Benchekroun S, Matthay KK. Infections in hospitalized children and young adults with acute leukemia in Morocco. Pediatr Blood Cancer. 2013 Jun; 60(6):916-22.
   View on PubMed
4. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. J Nucl Med. 2013 Apr; 54(4):541-8.
   View on PubMed
5. Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer. 2013 Jul; 60(7):1083-94.
   View on PubMed
6. Matthay KK. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption. Clin Cancer Res. 2013 Jan 15; 19(2):311-3.
   View on PubMed
7. Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, Vanbrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor Dosimetry Using [(124)I]m-iodobenzylguanidine MicroPET/CT for [(131)I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model. Mol Imaging Biol. 2012 Dec; 14(6):735-42.
   View on PubMed
8. French S, Dubois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. (131) I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May; 60(5):879-84.
   View on PubMed
9. Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834.
   View on PubMed
10. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 9; 107(8):1418-22.
    View on PubMed
11. Karski EE, Matthay KK, Neuhaus JM, Goldsby RE, Dubois SG. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013 Feb; 37(1):29-33.
    View on PubMed
12. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012 Oct 1; 30(28):3525-32.
    View on PubMed
13. Applebaum MA, Sambrano E, Lee S, Goldsby R, Matthay KK, DuBois SG. Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Apr-Jun; 27(2):e164-6.
    View on PubMed
14. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63.
    View on PubMed
15. Porzig A, Matthay KK, Dubois S, Pampaloni M, Damon L, Hawkins R, Goldsby R, Hollinger F, Fitzgerald P. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42.
    View on PubMed
16. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012 May 15; 18(10):2740-53.
    View on PubMed
17. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8.
    View on PubMed
18. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 1; 18(9):2679-86.
    View on PubMed
19. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med. 2012 Jan 4; 4(115):115ra3.
    View on PubMed
20. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy. Cancer Nurs. 2012 Jan-Feb; 35(1):19-28.
    View on PubMed

View on UCSF Profiles